A successful outsourced medicine begins with a complete product brief, not a request for a price. You will be able to map each handoff, choose the right manufacturing model, check a supplier’s quality controls, and approve packaging without creating regulatory or batch-release problems.
Key takeaways
- Give manufacturers specifications, quantities, testing, and packaging details before requesting quotes.
- Match formulation records, batch documents, and release checks at every production handoff.
- Confirm intellectual property, regulatory responsibilities, minimum batch size, and approval rights in writing.
- Audit licences, quality systems, packaging controls, and batch records before placing an order.
Start with a Product Brief That Can Be Quoted and Developed
A manufacturer cannot price a product accurately from a brand name and a tablet photograph. A usable product brief gives the team enough information to assess materials, equipment, testing, regulatory work, minimum batch size, lead time, and packaging.
- Name the target molecule, dosage form, composition and strength, including each active ingredient and its quantity per tablet, capsule, 5 mL, or dose.
- State the required product standard: quantitative formula, critical quality attributes, dissolution profile, impurity limits, assay range, microbiological limits, and stability requirements. A generic product must match defined quality and performance targets, not merely the reference product’s appearance.
- Specify the pack size and format, such as 10 tablets per blister, 100 mL bottle, or 1,000-vial shipper, plus the expected annual quantity and first-order quantity.
- Identify the target market, prescription or non-prescription category, required product approvals, and whether bioequivalence, validation, or other evidence is needed.
- Provide the brand name, artwork status, language, label claims, storage conditions, and preferred primary packaging. For injectables, state requirements for container-closure integrity, light protection, and formulation compatibility.
- Give the requested delivery date, dispatch location, purchase-order process, and any forecast or supply commitment.
- Define ownership of the formulation, brand, artwork, dossier, specifications, and batch records, then require a confidentiality agreement and quality agreement before development begins.
This product brief lets a third party pharma products manufacturing partner separate development costs from routine production costs. Ask for a written quotation that lists assumptions, exclusions, testing, tooling, minimum batch size, lead time, and product-specific permissions.
Track the Handoff from Formulation to Released Commercial Batch
A quotation becomes a manufacturable product only after formulation development turns the product brief into measurable specifications. For a generic, confirm the quantitative composition, critical quality attributes, dissolution behaviour, impurity limits, stability plan, and bioequivalence evidence where required.
A manufacturing licence alone does not authorise every prescription product; verify product-specific permissions and the Schedule H, H1, or X category.
1. Prepare the product specification and confirm the target molecule or composition, dosage form, strength, pack size, market, annual quantity, artwork status, and delivery schedule.
2. Develop the formulation, then document the approved composition, process parameters, tests, and acceptance limits in the master formula.
3. Make a pilot batch to expose problems in blending, granulation, filling, dissolution, sterility, or stability before committing production resources.
4. Review pilot results and produce a scale-up batch. Compare its assay, dissolution, impurities, microbial quality, and yield with the agreed specification.
5. Authorise the commercial process after process validation or the required qualification work. Record deviations, investigations, and approved changes.
6. Manufacture the commercial batch, test samples through quality control, and release it with a certificate of analysis and batch record review.
Release does not mean dispatch yet. Select primary packaging against the product’s risks: a tablet blister’s moisture barrier, or an injectable’s container-closure integrity, light protection, extractables, leachables, and compatibility.
Before packing, approve artwork, clear the line, segregate strengths, reconcile printed components, verify barcodes or vision checks, and destroy obsolete artwork under control. The released packed batch then moves with the packing list and invoice; the agreement must assign responsibility for recalls, complaints, records, changes, and inspection access.
Choose the Manufacturing Model and Lock Down Ownership
Choose the model by deciding who controls the formula, approvals, records, and production site—not merely who prints the carton.
| Option | What it means | Who usually owns the key assets |
|---|---|---|
| Contract manufacturing | You commission defined development or production work under a manufacturing agreement. | Ownership of formulation, dossier, artwork, and batch records is negotiated; the manufacturer produces to agreed specifications. |
| Third-party manufacturing | You buy finished batches from an external licensed manufacturer and sell them under your brand. | You usually control the brand, artwork, specifications, and market obligations; the manufacturer controls its process records. |
| Loan-licence manufacturing | You obtain permission to manufacture through another licensee’s premises, equipment, and technical staff. | The licence holder operates the site; the agreement must state who owns the product approval, formula, records, and release decision. |
| Private labelling | An existing product is sold under your name, often with limited formulation changes. | You own or control the brand and label; formula and dossier ownership remain with the manufacturer unless transferred in writing. |
| In-house production | Your company develops and makes the product at its own facility. | You control the site, formula, validation, batch records, release, and regulatory submissions. |
Do not treat a manufacturing licence as product approval. Confirm the dosage form, approved formulation, product-specific permissions, and market category before ordering.
Put these points in the agreement:
- Responsibility for specifications, validation, batch release, deviations, complaints, recalls, inspections, and records
- Approval thresholds for changes to API source, excipient grade, site, container, label text, or analytical method
- Ownership and access rights for the formula, dossier, stability data, artwork, and batch records
For supplements, also assign responsibility for FSSAI category, permitted ingredients, claims, and label compliance.
Audit the Manufacturer Before You Place the Purchase Order
Do not issue a purchase order until the manufacturer proves that it can legally make your exact product and release it under controlled conditions. Ask for copies of the manufacturing licence, product permission or approved formulation, site address, dosage-form scope, and GMP evidence such as a current inspection report or certificate.
| Control | Verify before selection | Failure exposed |
|---|---|---|
| Licence and approval | Manufacturing licence plus product-specific permission | Unauthorised manufacture |
| Materials | Approved suppliers, identity testing, material status, traceability, and impurity, microbiological, elemental or nitrosamine controls where relevant | Substandard inputs |
| Testing | Validated methods, specifications, stability data, and a finished-product certificate of analysis | False release confidence |
| Records | Master formula, batch manufacturing record, equipment logs, deviations, investigations, complaints and recall records | Untraceable defects |
| Release | Named quality unit, independent review, approved certificate of analysis and documented batch-release decision | Shipment before approval |
A manufacturing licence does not replace product permission. Confirm that the approved strength, formulation, manufacturing site and pack match your order.
Put responsibilities in a quality agreement: validation, batch release, change control, regulatory inspection access and record retention must have named owners. Classify changes as critical, major or minor, and require approval before changes to the API source, excipient grade, filling line, sterilisation cycle, container or analytical method.
For injectables, do not accept sterility testing as proof of sterility. Check validated sterilisation or aseptic processing, environmental monitoring, container-closure integrity and adverse-trend investigations. Also inspect line clearance, printed-component reconciliation, barcode or vision checks and obsolete-artwork destruction.
If you assess kelps healthcare, request this same evidence rather than relying on a catalogue or a single certificate.
Make Packaging Protect the Product and Survive Artwork Approval
Choose the primary pack from the product’s stability risk, not its purchase price. A blister pack using PVC/PVDC can protect tablets and capsules from moisture better than plain PVC; an HDPE bottle may suit high-count packs but needs a compatible closure and desiccant assessment.
| Pack | Check before approval | Common failure |
|---|---|---|
| Blister pack | PVC/PVDC barrier, foil seal, pocket size, push-through force | Moisture ingress or tablet breakage |
| HDPE bottle | Resin, cap torque, induction seal, desiccant, light protection | Loose closure or uncontrolled humidity |
| Injectable container | Glass or plastic compatibility, extractables, leachables, adsorption | Leachables or loss of potency |
| Sterile pack system | Sterility and container-closure integrity, stopper, seal, transport stress | Contamination or a hidden leak |
Approve artwork against the product specification, approved formulation, market rules, and the latest packaging mock-up. Check strength, dosage form, batch-number and expiry fields, storage statement, warnings, barcode, manufacturer details, and net contents; sign one controlled proof and withdraw obsolete files.
A new foil, resin, stopper, ink, desiccant, or pack size needs documented change control and a stability assessment before use.
Control the packaging line with:
- Line clearance before startup and after completion
- Physical segregation of products and strengths
- Barcode or vision verification of components
- Reconciliation of issued, used, rejected, and returned printed materials
- Recorded destruction of obsolete artwork and damaged labels
Before dispatch, match the released batch to the certificate of analysis, packing list, invoice, approved artwork, and transport requirements. For injectables, retain sterility, environmental, sterilization or aseptic-processing, and container-closure integrity records; do not treat a passing sterility test as proof of a weak process.
Frequently asked questions
What should a product brief include before requesting a manufacturing quote?
Include the dosage form, strength, active ingredients, excipients, target quantity, quality tests, regulatory needs, minimum batch size, lead time, and packaging format.
How can you track a product from formulation to commercial batch release?
Use controlled handoff records that connect the approved formula, specifications, manufacturing instructions, test results, deviations, packaging records, and final batch-release decision.
What must you settle before choosing a third-party pharma manufacturing model?
Define who owns the formula, artwork, dossiers, tooling, and test methods, then assign manufacturing, testing, regulatory, complaint, and release responsibilities in the contract.
What should you check during a manufacturer audit?
Review the manufacturing licence, premises, equipment, quality-control laboratory, batch records, deviation system, training records, storage conditions, and previous corrective actions.
How do you make pharmaceutical packaging both protective and approval-ready?
Select materials that protect the dosage form, verify pack compatibility and transport conditions, and approve artwork against the product specifications, mandatory declarations, batch fields, and version number.
